

		Lead	Preclinical	Phase I	Phase II	Phase III
Safinamide	Adjunctive to dopamine agonist Early Stage PD	[Progress bar spanning Lead, Preclinical, Phase I, Phase II, and Phase III]				
	Adjunctive to levodopa Mid to late stage PD	[Progress bar spanning Lead, Preclinical, Phase I, Phase II, and Phase III]				
Ralfinamide	Neuropathic Low Back Pain	[Progress bar spanning Lead, Preclinical, Phase I, Phase II, and Phase III]				
	Inflammatory pain	[Progress bar spanning Lead, Preclinical, Phase I, and Phase II]				
HF 0220	Neuroprotection	[Progress bar spanning Lead, Preclinical, Phase I, and Phase II]				
HF 0299	Neuropathic pain	[Progress bar spanning Lead, Preclinical, Phase I, and Phase II]				
NW 3509	Schizophrenia/Mania	[Progress bar spanning Lead and Preclinical]				
HF 1220 Series	Neuroprotection	[Progress bar spanning Lead and Preclinical]				
IC	CNS-related disorders/pain	[Progress bar spanning Lead and Preclinical]				

- Newron is undertaking Phase III trials with safinamide for the treatment of PD on behalf of its partner Merck Serono
- IC = Ion Channel Program
- HF 1020 in preclinical development for asthma is part of Newron's equity holding in Trident
- HF 0420 rights were returned to the inventor, with potential future milestones and royalties due to Newron